人民财讯10月28日电，ST诺泰(688076)10月28日公告，近日公司参加了国家组织药品联合采购办公室组 织的第十一批全国药品集中采购的投标工作，公司产品阿戈美拉汀片拟中选本次集中采购。 ...

证券代码：688076 证券简称：ST 诺泰 公告编号：2025-070 江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露阿戈美拉汀片拟中选第十一批全国药 品集中采购的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）参加了 国家组织药品联合采购办公室（以下简称"联采办"）组织的第十一批全国药品 集中采购的投标工作，公司产品阿戈美拉汀片拟中选本次集中采购。现将相关情 况公告如下。 一、 拟中选产品情况 | 拟中选 药品通 | 剂型 | 适应症 | 规格 | 包装规 | 拟中选价 | 拟中标数 | 拟供应地 | | --- | --- | --- | --- | --- | --- | --- | --- | | 用名 | | | | 格 | 格（元/盒） | 量 | 区 | | 阿戈美 | | 成人抑 | | 7 片/ | | 不低于 | 四川、吉 | | 拉汀片 | 片剂 | 郁症 | 25mg | 板，4 板/盒 | 8.40 | 万片 206 | 林、黑龙 ...

Core Viewpoint - The storage chip market is experiencing an unprecedented price surge driven by AI demand, leading to a structural imbalance in supply and demand [1][2][6]. Group 1: Price Surge and Market Dynamics - The price increase in the storage chip market has been ongoing for over six months, with no signs of slowing down as it enters the fourth quarter [3][5]. - Recent data shows that the price of DDR4 16Gb 3200 has surged to $13.00, a 30% increase from the previous week, while the price of 512Gb Flash Wafer has risen over 20% since October [3][4]. - The overall price of DRAM, including HBM, is expected to increase by 13%-18% in the fourth quarter [4]. Group 2: AI Demand and Supply Chain Impact - The core driver of the current price surge is the explosive demand for HBM driven by AI, which is disrupting the traditional supply-demand balance in the storage industry [2][6]. - Major manufacturers are prioritizing production capacity for high-end Server DRAM and HBM, leading to a shortage of older products like DDR4 and LPDDR4X, which may last until the first half of 2026 [2][9]. - The demand for AI infrastructure is projected to reach $400 billion this year, significantly increasing the need for storage chips [6]. Group 3: Industry Response and Strategies - Domestic storage manufacturers are actively stockpiling inventory and raising prices in anticipation of continued demand and price increases [10][11]. - Some companies, like Jiangbolong, are adopting a stockpiling strategy to ensure profitability, while others, like Langke Technology, are focusing on inventory clearance to reduce volatility [10][11]. - Companies are also exploring high-value areas such as HBM and advanced packaging to capitalize on the structural changes in the market [12]. Group 4: Market Reactions and Future Outlook - The capital market has reacted positively to the ongoing "super cycle," with significant stock price increases for storage chip companies [5]. - The transition to DDR5 and the slowdown in the shift from DDR3 to DDR4 in consumer electronics indicate a strategic response to the supply constraints [9][12]. - As HBM production capacity is expected to increase, there may be an oversupply of HBM3e by 2026, but HBM4 is anticipated to remain in short supply due to its technical barriers [12].

Core Viewpoint - The company, Nuotai Bio (688076.SH), reported a robust performance in Q3 2025, with revenue of 1.527 billion yuan, a year-on-year increase of 21.95%, and a net profit of 445 million yuan, up 26.92%, driven by the expanding GLP-1 market and its commitment to "time and technology leadership" [1][2]. Group 1 - The growth in revenue and profit is primarily attributed to the increasing demand for peptide drugs, particularly GLP-1 targeted drugs, which has been a core driver of the company's performance in recent years [1]. - The global peptide drug market has been growing steadily, reaching a size of 43 billion USD in 2020, with a growth rate of nearly 16% since 2007 [1]. - Sales of GLP-1(R) drugs are projected to exceed 50 billion USD in 2024, with semaglutide contributing over half of the sales, positioning Nuotai Bio as a major beneficiary of this trend [1]. Group 2 - The company is enhancing its core competitiveness through various initiatives, including the establishment of a commercial production facility for oligonucleotides, expected to be completed by 2025, which will have a capacity of 1,000 kg for oligonucleotides and 200 kg for PEG-linked peptides [2]. - Nuotai Bio is actively pursuing external growth opportunities, including a strategic partnership with Novozymes to establish a joint venture focused on synthetic biology technology [2]. - The collaboration with DeepTech in AI drug development aims to leverage AI technology to transform the biopharmaceutical industry, creating a comprehensive value system encompassing intelligent R&D and precision manufacturing [2]. Group 3 - The company plans to leverage its advantages in peptide and small molecule drug development to build an XDC technology platform through internal development and strategic investments, focusing on various coupling platforms [3]. - Efforts are being made to establish a high-quality international business development team to explore new business directions [3].

Group 1 - Cinda Biologics has reached a global strategic cooperation with Takeda Pharmaceutical, aiming to accelerate the development of new generation IO and ADC therapies, with a total deal value potentially reaching $11.4 billion [1] - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with an upfront payment of $1.2 billion, including $100 million in strategic equity investment [1] - Cinda Biologics is expected to maximize the long-term commercialization prospects of IBI363 and IBI343 globally, leveraging Takeda's strong presence in the gastrointestinal oncology field [1] Group 2 - Shouyao Holdings announced that its self-developed RET inhibitor, SY-5007, has received acceptance for a new drug application for treating RET fusion-positive locally advanced or metastatic non-small cell lung cancer [2] - SY-5007 is a highly selective small molecule RET tyrosine kinase inhibitor and is among the fastest progressing fully domestic RET inhibitors in clinical research [2] - If approved, SY-5007 will fill the gap in domestic RET inhibitors, as currently only two RET inhibitors, pralsetinib and selpercatinib, have been approved globally [2] Group 3 - Dongya Pharmaceutical has been ordered to rectify discrepancies between the use of raised funds and disclosures in its IPO prospectus, as identified by the Zhejiang Securities Regulatory Bureau [3] - The company failed to timely follow the review procedures regarding the actual use of raised funds, leading to inaccurate disclosures [3] - This incident highlights the need for listed companies to enhance transparency and compliance in information disclosure [3] Group 4 - ST Nuotai reported a revenue of approximately 1.527 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 21.95%, with a net profit of about 445 million yuan, up 26.92% [4] - In the third quarter, the company achieved revenue of approximately 479 million yuan, a year-on-year growth of 13.82%, and a net profit of about 134 million yuan, increasing by 9.27% [4] - The growth in ST Nuotai's performance is attributed to the rapid increase in demand for peptide raw materials, with oral peptide products expected to become a new growth point for the company [4]

Core Viewpoint - The company, Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd., is set to hold a performance briefing for the third quarter of 2025 to discuss its operational results and financial status with investors [8][9]. Financial Data - The third quarter financial report for 2025 has been released, and it is noted that the financial statements are unaudited [3][4]. - The report includes key financial data and indicators, although specific figures are not detailed in the provided text [3]. Shareholder Information - The company has confirmed the total number of ordinary shareholders and the status of major shareholders, although specific details are not provided [5]. Investor Communication - The performance briefing will take place on October 30, 2025, from 15:00 to 16:00 at the Shanghai Stock Exchange Roadshow Center, and it will be conducted in an interactive online format [8][9]. - Investors are encouraged to submit questions in advance through the designated channels, and the company will address common concerns during the briefing [10][11]. Company Responsibility - The board of directors and senior management have assured the accuracy and completeness of the quarterly report, taking legal responsibility for its content [2][7].

Core Viewpoint - The article summarizes significant announcements from various listed companies in the Shanghai and Shenzhen stock markets, highlighting potential investment opportunities and risks based on recent developments and financial performance. Group 1: Company Announcements - Tianpu Co., Ltd. warns that its stock price has significantly deviated from its fundamentals, with a cumulative increase of 246.02% from August 22 to October 22, indicating a potential for rapid decline [4] - Shenzhen Sanda A plans to sell stakes in several subsidiaries to focus on its core business, including 80% of Zhongdian Continental Environmental Technology [5][6] - Zhongchong Co., Ltd. received an administrative regulatory measure from the Shandong Securities Regulatory Bureau for failing to announce a significant change in shareholding [7] - Construction Machinery has reported a net loss of 447 million yuan for the first half of 2025, marking three consecutive years of losses [8] - Junshi Biosciences announced that its subsidiary passed a recent FDA inspection, indicating compliance with CGMP standards [9] Group 2: Financial Performance - Duofuduo reported a net profit increase of 407.74% year-on-year for the first three quarters of 2025, with a revenue of 6.73 billion yuan [17] - Weihuaxincai achieved a net profit growth of 250.04% year-on-year in Q3, with revenues of 660 million yuan [18] - Guangdong Jianke reported a net profit increase of 190.62% year-on-year for the first three quarters, despite a revenue decline [19] - Xianggang Technology reported a net profit increase of 186.19% year-on-year for the first three quarters, with revenues of 742 million yuan [20] - Defu Technology reported a net profit increase of 132.63% year-on-year for the first three quarters, driven by increased copper foil sales [21] Group 3: Major Transactions and Investments - Tangrenshen plans to establish two investment funds with a total investment of 11.04 million yuan to focus on the agricultural sector [13] - Farsen intends to sell a 10% stake in Bekaert Steel Cord, constituting a major asset restructuring [14] - Shikong Technology plans to acquire 100% of Jiahe Jingwei, entering the storage sector [15] - Jiangsu New Energy's controlling shareholder is investing in offshore wind power projects and will manage the project companies [11][12] Group 4: Shareholder Actions - Qianyuan Pharmaceutical's shareholder plans to reduce its stake by up to 3% [42] - Zhengfan Technology's board members plan to collectively reduce their holdings by up to 1.88% [43]

Group 1: Company Performance - China Unicom reported a 1.0% increase in revenue to 292.985 billion yuan for the first three quarters of 2025, with a net profit of 8.772 billion yuan, up 5.2% year-on-year [1] - Tonghuashun's third-quarter revenue reached 1.481 billion yuan, a 56.72% increase, with a net profit of 704 million yuan, up 144.5% year-on-year [2] - Duofu Du achieved a net profit of 78.054 million yuan for the first three quarters, a significant increase of 407.74% compared to the previous year [11] - Wehua New Materials reported a third-quarter net profit of 25.384 million yuan, a 250.04% increase year-on-year [12] - Xianggang Technology's net profit for the first three quarters grew by 186.19% to 95.471 million yuan [13] Group 2: Stock and Market Activity - Tianpu Co. warned of potential rapid declines in stock price due to a 246.02% increase since August 22, indicating a significant deviation from the company's fundamentals [3] - Deep Sanda A announced plans to sell stakes in several subsidiaries to focus on core business operations [4] - Jiangsu New Energy's controlling shareholder plans to invest in offshore wind power projects and will manage the projects through the company [10] Group 3: Regulatory and Compliance Issues - Zhongchong Co. received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to announce a significant change in shareholding [5] - Two consecutive years of losses were reported by Lianban Construction Machinery, prompting a risk warning for investors [6] Group 4: Corporate Developments - Junshi Biosciences' subsidiary passed a CGMP inspection by the FDA, marking its second successful inspection [8] - Xinguang Optoelectronics announced the lifting of restrictions on its chairman, allowing him to resume normal duties [9] - Defu Technology plans to invest an additional 1 billion yuan in special copper foil production facilities [30]

Core Insights - ST诺泰 reported a revenue of 1.527 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 21.95% [1] - The net profit attributable to shareholders for the same period was 445 million yuan, showing a year-on-year increase of 26.92% [1] - In the third quarter alone, the company achieved a revenue of 479 million yuan, which is a year-on-year growth of 13.82% [1] - The net profit for the third quarter was 134 million yuan, reflecting a year-on-year increase of 9.27% [1]

Group 1 - Tianpu Co., Ltd. warns that its stock price has significantly deviated from its fundamentals, with a potential for rapid decline after a 246.02% increase from August 22 to October 22 [3] - Shenzhen Sanda A plans to sell stakes in several subsidiaries to focus on its core business, including 80% of Zhongdian Intercontinental Environmental Technology [4] - Zhongchong Co., Ltd. received an administrative regulatory measure from the Shandong Securities Regulatory Bureau for failing to announce a significant change in shareholding [5] Group 2 - Construction Machinery has reported a net loss for three consecutive years, with a net profit of -447 million yuan for the first half of 2025 [6] - Junshi Biosciences' subsidiary passed a CGMP inspection by the FDA, indicating compliance with manufacturing standards [7] - Xinguang Optoelectronics announced the lifting of detention measures against its chairman, indicating normal operations [8] Group 3 - Jiangsu New Energy's controlling shareholder plans to invest in offshore wind power projects and will manage the project companies through the listed company [10] - Duofluorid's net profit for the first three quarters increased by 407.74%, with a revenue of 6.729 billion yuan [12] - Weihuaxin Materials reported a 250.04% increase in net profit for the third quarter, with revenue of 223 million yuan [13] Group 4 - Xianggang Technology's net profit for the first three quarters increased by 186.19%, with a revenue of 742 million yuan [14] - Defu Technology's net profit increased by 132.63% in the first three quarters, with a revenue of 8.5 billion yuan [15] - Taishan Petroleum reported a 112.32% increase in net profit for the first three quarters, with a revenue of 2.395 billion yuan [16] Group 5 - Kaisheng New Materials reported a 121.56% increase in net profit for the first three quarters, with a revenue of 774 million yuan [17] - Guangku Technology's net profit increased by 106.61% in the first three quarters, with a revenue of 998 million yuan [18] - Xinong Co., Ltd. reported a 105.68% increase in net profit for the third quarter, with a revenue of 837 million yuan [19] Group 6 - Mairande's net profit increased by 36.71% in the third quarter, with a revenue of 103 million yuan [20] - ST Nuotai reported a 26.92% increase in net profit for the first three quarters, with a revenue of 1.527 billion yuan [21] - Anke Rui's net profit increased by 21.31% in the first three quarters, with a revenue of 837 million yuan [22] Group 7 - Weisheng Information reported a 12.24% increase in net profit for the first three quarters, with a revenue of 2.112 billion yuan [23] - Action Education plans to distribute a cash dividend of 5 yuan per 10 shares, with a net profit increase of 10.39% [24] - Henghui Security reported a 12.85% decrease in net profit for the first three quarters, with a revenue of 880 million yuan [25] Group 8 - China Shipbuilding Han Guang reported a 9.44% decrease in net profit for the first three quarters, with a revenue of 875 million yuan [26] - Sichuan Chengyu's subsidiary signed a sand and gravel supply contract worth up to 100 million yuan [28][29] - Yuegui Co., Ltd.'s subsidiary signed a mining rights transfer contract for a quartz rock mine with a reserve of 18.163 million cubic meters [30]